Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (21-30 of 205) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2024
Reply to Y. Xia et alSebastian Bauer, Jonathan A Fletcher, Daniel Rauh, et al.
Cancer Investigation|April 9, 2004
Biology of gastrointestinal stromal tumors: KIT mutations and beyondAnette Duensing, Michael C Heinrich, Christopher D Fletcher, et al.
Human Pathology|July 3, 2002
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterationsMichael C Heinrich, Brian P Rubin, B Jack Longley, et al.
Cancer|June 19, 2009
Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesotheliomaRachel E Factor, Paola Dal Cin, Jonathan A Fletcher, et al.
Molecular Cancer Therapeutics|June 2, 2012
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathwaysXinqi Wu, Jingjing Li, Meijun Zhu, et al.
Cancer Research|November 5, 2002
Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implicationsQing Chang, Yu Li, Morris F White, et al.
Genes, Chromosomes & Cancer|May 12, 2007
Genomic and functional evidence for an ARID1A tumor suppressor roleJianmin Huang, Yan-Ling Zhao, Yu Li, et al.
Plos One|January 19, 2012
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanomaXinqi Wu, Meijun Zhu, Jonathan A Fletcher, et al.
Anti-Cancer Drugs|March 5, 2005
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylateStefanos V Labropoulos, Jonathan A Fletcher, Andre M Oliveira, et al.
Endocrine Pathology|December 17, 2009
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomasPeter M Sadow, Michael C Heinrich, Christopher L Corless, et al.
Pageof 21

Showing results (21-30 of 205) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2024
Reply to Y. Xia et alSebastian Bauer, Jonathan A Fletcher, Daniel Rauh, et al.
Cancer Investigation|April 9, 2004
Biology of gastrointestinal stromal tumors: KIT mutations and beyondAnette Duensing, Michael C Heinrich, Christopher D Fletcher, et al.
Human Pathology|July 3, 2002
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterationsMichael C Heinrich, Brian P Rubin, B Jack Longley, et al.
Cancer|June 19, 2009
Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesotheliomaRachel E Factor, Paola Dal Cin, Jonathan A Fletcher, et al.
Molecular Cancer Therapeutics|June 2, 2012
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathwaysXinqi Wu, Jingjing Li, Meijun Zhu, et al.
Cancer Research|November 5, 2002
Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implicationsQing Chang, Yu Li, Morris F White, et al.
Genes, Chromosomes & Cancer|May 12, 2007
Genomic and functional evidence for an ARID1A tumor suppressor roleJianmin Huang, Yan-Ling Zhao, Yu Li, et al.
Plos One|January 19, 2012
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanomaXinqi Wu, Meijun Zhu, Jonathan A Fletcher, et al.
Anti-Cancer Drugs|March 5, 2005
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylateStefanos V Labropoulos, Jonathan A Fletcher, Andre M Oliveira, et al.
Endocrine Pathology|December 17, 2009
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomasPeter M Sadow, Michael C Heinrich, Christopher L Corless, et al.
Pageof 21